

GENERAL

Kidney Transplant: Immunosuppressive Therapies and Complications

Armaan batra*

* Correspondence: Armaan batra

Received: 02 August 2025

Published: 02 September 2025

Volume 12, Issue 3 (Jul–Sep 2025)

Article no.: e159

Open access · free to read

Introduction

The kidneys are bean-shaped organs located in the abdomen on either side of the spine. It is about 10-12 cm long and 5-7 cm wide. The outer surface of the kidney is smooth and coloured dark red or brown. Inside the kidney, the next he is divided into two areas;

- Renal cortex
- Renal medulla.

The renal cortex is the outer layer of the kidney, appears light-colored, and consists of many small filtering units called nephrons. The renal medulla is the inner part of the kidney and appears darker in color. It contains the renal cone, a cone-shaped structure containing collecting ducts and tubules that concentrate urine.

Kidneys play an important role in filtering waste products from the blood and regulating fluid balance.

Kidney transplantation is the preferred treatment for end-stage renal disease, offering better quality of life and survival compared to dialysis. Immunosuppression is a critical component of kidney transplant care to prevent rejection and ensure long-term graft survival. The choice of immunosuppressive therapy depends on various factors, including recipient and donor characteristics, comorbidities, and the risk of rejection. This review summarizes

the current immunosuppressive strategies in kidney transplantation, including induction therapy, maintenance therapy, and treatment of rejection. We also discuss the potential risks and side effects associated with immunosuppressive drugs and their impact on long-term outcomes.

Introduction:

Kidney transplantation is a surgical procedure that is used to treat patients with end-stage renal disease. It is a well-established therapy that has been performed for over 50 years, and has become the preferred treatment for patients with end stage renal disease who are medically suitable for transplantation. In this

review, we will discuss the history, indications, contraindications, surgical techniques, immunosuppressive therapies, complications, and outcomes of kidney transplantation

History:

The first successful kidney transplant was performed in 1954 by Dr. Joseph Murray and his team at the Peter Bent Brigham Hospital in Boston. The recipient was a 23-year-old man with end-stage renal disease, and the donor was his identical twin brother. The transplant was successful, and the recipient lived for eight years with a functioning kidney transplant. Since then, advances in immunosuppressive therapies and surgical techniques have significantly improved the outcomes of kidney transplantation.

Indications:

Kidney transplantation is indicated for patients with end-stage renal disease who are not able to be treated with dialysis alone. Patients who are good candidates for transplantation are those who are medically stable and do not have any significant comorbidities that would make transplantation unsafe. In addition, patients who have a living donor are preferred over those who require a deceased donor transplant.


Surgical Techniques:

Kidney transplantation can be performed using either an open or a laparoscopic technique. In an open procedure, a large incision is made in the abdomen to access the kidney. In a laparoscopic procedure, several small incisions are made in the abdomen and a camera and instruments are inserted to perform the

surgery. The decision of which technique to use depends on the individual patient and the surgeon's preference.

Immunosuppressive Therapies:

Immunosuppressive therapies are used to prevent rejection of the transplanted kidney. These therapies include calcineurin inhibitors, such as tacrolimus and cyclosporine, as well as antiproliferative agents, such as mycophenolate mofetil and azathioprine. In addition, corticosteroids are often used as part of the immunosuppressive regimen.



?Induction Therapy:

Induction therapy is used to prevent acute rejection in the early post-transplant period. The commonly used induction agents include anti-thymocyte globulin (ATG), interleukin-2 receptor antagonists (IL-2RA), and monoclonal antibodies against CD52 or CD25. ATG has been associated with a higher risk of infections and malignancies, whereas IL-2RA has a lower risk of side effects.

Maintenance Therapy:

Maintenance immunosuppression is used to prevent long-term rejection and ensure graft survival. The most commonly used maintenance drugs include calcineurin inhibitors (CNIs), mycophenolate mofetil (MMF), and corticosteroids. CNIs are associated with nephrotoxicity and cardiovascular complications, while MMF has a lower risk of side effects. The use of corticosteroids has declined over the years due to their adverse effects, but

they are still used in some transplant centers.

Types of Immunosuppressive Therapies:

There are several types of immunosuppressive therapies used after kidney transplantation, including calcineurin inhibitors, antiproliferative agents, and corticosteroids.

Calcineurin inhibitors (CNIs) are a class of immunosuppressive drugs that inhibit the activity of calcineurin, a protein that is involved in the activation of T cells. The two most commonly used CNIs are tacrolimus and cyclosporine. Tacrolimus has been shown to be more effective than cyclosporine in preventing acute rejection after kidney transplantation. However, tacrolimus is associated with a higher risk of nephrotoxicity, and may be more difficult to manage than cyclosporine due to its narrow therapeutic index.

Antiproliferative agents are a class of immunosuppressive drugs that inhibit the proliferation of T cells. The two most commonly used antiproliferative agents are mycophenolate mofetil (MMF) and azathioprine. MMF has been shown to be more effective than azathioprine in preventing acute rejection after kidney transplantation. However, MMF is associated with a higher risk of gastrointestinal side effects, and may not be tolerated by all patients.

Corticosteroids are a class of immunosuppressive drugs that are used to suppress inflammation and prevent rejection. The most commonly used corticosteroid after kidney transplantation is prednisone. However, corticosteroids are associated with several side effects, including weight gain, diabetes, hypertension, and osteoporosis.

Mechanisms of Action:

The different types of immunosuppressive therapies used after kidney transplantation work through different mechanisms. CNIs, such as tacrolimus and cyclosporine, inhibit the activity of calcineurin, a protein that is involved in the activation of T cells. This leads to a reduction in the production of cytokines and the proliferation of T cells, which in turn leads to a reduction in the activity of the immune system.

Antiproliferative agents, such as MMF and azathioprine, inhibit the proliferation of T cells by blocking the synthesis of purines, which are essential for DNA synthesis. This leads to a reduction in the number of T cells, which in turn leads to a reduction in the activity of the immune system.

Corticosteroids, such as prednisone, suppress inflammation and prevent rejection by inhibiting the production of cytokines and the proliferation of T cells. Corticosteroids also have an effect on other immune cells, such as B cells and macrophages.

Tacrolimus

Tacrolimus is an immunosuppressive drug commonly used after kidney transplantation to prevent rejection of the transplanted organ. It belongs to a class of drugs known as calcineurin inhibitors.

Tacrolimus works by suppressing the activity of the immune system and specifically blocking the activation of her T cells, which are responsible for initiating the immune response that can lead to rejection of the transplanted kidney. By reducing the activity of her T cells, tacrolimus prevents rejection and prolongs the survival of transplanted kidneys.

Tacrolimus is usually given orally in capsule or tablet form and is usually started immediately after transplantation. The dose of tacrolimus is adjusted based on the blood levels of the drug to achieve therapeutic levels while minimizing the risk of side effects.

Complications:

Complications of kidney transplantation include rejection, infection, and complications related to the immunosuppressive therapy. Acute rejection can occur within the first few months after transplantation, and can

be treated with increased immunosuppression. Chronic rejection can occur over time and can lead to loss of kidney function. Infections can also occur, particularly in the first few months after transplantation, and can be severe in immunosuppressed patients.

Surgical Complications:

Surgical complications are common after kidney transplantation, particularly during the early postoperative period. The most common surgical complications include bleeding, thrombosis, and wound infections.

Bleeding can occur as a result of surgical trauma, particularly during the anastomosis of the renal vessels. The incidence of bleeding after kidney transplantation varies between 5% and 15%. Risk factors for bleeding include the use of anticoagulant medications, previous abdominal surgeries, and the presence of renal artery stenosis. The management of bleeding depends on its severity, but may include blood transfusions, surgical exploration, and embolization.

Thrombosis can occur as a result of technical errors during the surgical procedure or as a result of hypercoagulable states. The incidence of thrombosis after kidney transplantation is low, ranging from 0.5% to 5%. Risk factors for thrombosis include the use of ABO-incompatible grafts, donor age, and prolonged cold ischemia time. The management of thrombosis depends on its severity, but may include surgical exploration, thrombectomy, or retransplantation.

Wound infections can occur as a result of contamination of the surgical site during the operation or as a result of colonization of the wound by bacteria. The incidence of wound infections after kidney transplantation varies between 3% and 20%. Risk factors for wound infections include diabetes, obesity, smoking, and the use of immunosuppressive medications. The management of wound infections may include wound debridement, antibiotic therapy, and surgical drainage.

Immunosuppressive-related Complications:

Immunosuppressive-related complications are common after kidney transplantation, particularly during the long-term postoperative period. The most common immunosuppressive-related complications include infections, malignancies, and metabolic abnormalities.

Infections can occur as a result of the suppression of the patient's immune system by immunosuppressive medications. The incidence of infections after kidney transplantation varies between 20% and 50%. The most common infections include urinary tract infections, pneumonia, and cytomegalovirus

(CMV) infection. Risk factors for infections include older age, diabetes, and the use of high-dose immunosuppressive medications. The management of infections may include antibiotic therapy, antiviral therapy, or reduction of the dose of immunosuppressive medications.

Patients receiving immunosuppressants including prograf are at higher risk occurrence of lymphoma and other malignancies, especially cutaneous. A risk emerges related to intensity and duration of immunosuppression rather than application specific agent. The person's skin is examined as usual in people at high risk of skin cancer. Change; protective equipment should be worn to limit exposure to sunlight and uv rays wearing and using a broad-spectrum sunscreen with a high spf. Post-transplant lymphoproliferative disease (ptld) has been reported. Immunocompromised organ transplant recipients. Most ptld events occur associated with epstein-barr virus (ebv) infection. This is where ptld is most likely to be at risk a population that is ebv seronegative and includes many infants. During treatment he will monitor ebv serology.

Metabolic abnormalities can occur as a result of the use of immunosuppressive medications. The most common metabolic abnormalities include hypertension, hyperlipidemia, and diabetes. The incidence of metabolic abnormalities after

kidney transplantation varies between 30% and 60%. Risk factors for metabolic abnormalities include older age, obesity, and the use of high-dose immunosuppressive medications.

Diabetes may develop new after transplant. It is reversible in some patients. African American and Hispanic Kidney Transplant Patients Risk is increasing. Blood sugar levels should be carefully monitored

Calcineurin inhibitors

It is widely used in post-transplant immunosuppressive therapy and has secured an important place in modern post-transplant solid organ transplant care for the prevention of acute disease. Graft rejection, outgrowth and survival. Cyclosporin (Neoral, Novartis) and tacrolimus (Prograf, Astellas). It is a calcineurin inhibitor that suppresses the activation of T lymphocytes mainly by inhibiting their production. Calcineurin inhibitor of cytokines, especially IL-2. Associated with multiple toxicities, often administered reliance. Hirsutism, gingival hypertrophy, hypertension and hyperlipidemia is more common with cyclosporine treatment rather than tacrolimus. Neurotoxicity, alopecia, and possibly post-transplantation Diabetes occurs more frequently with tacrolimus treatment than with cyclosporine treatment. Possible drug Recognizing Interactions Is Important, Vigilance Is Important Required if final remedy is added or adjusted Effects on calcineurin inhibitor levels, usually induction or Inhibition of cytochrome P450-3A signaling. Both calcineurin inhibitors can be administered intravenously or orally

Conclusion:

Kidney transplantation is a well-established therapy for patients with end-stage renal disease. Advances in immunosuppressive therapies and surgical techniques have significantly improved the outcomes of kidney transplantation, and patients who receive a kidney transplant have a significantly improved quality of life and longer life expectancy compared to those on dialysis.

References

1. Neuwirt, H., Rudnicki, M., Schratzberger, P. *et al.* Immunosuppression after renal transplantation. *memo* 12, 216?221 (2019).
<https://doi.org/10.1007/s12254-019-0507-4>
2. Kalluri HV, Hardinger KL. Current state of renal transplant immunosuppression: Present and future. *World J Transplant.* 2012 Aug 24;2(4):51-68. doi: 10.5500/wjt.v2.i4.51. PMID: 24175197; PMCID: PMC3782235.
3. Webster AC, Playford EG, Higgins G, Chapman JR, Craig JC. Interleukin 2 receptor antagonists for renal transplant recipients: A meta-analysis of randomized trials. *Transplantation.* 2004;77(2):166? 76.
4. Szczech LA, Berlin JA, Aradhye S, Grossman RA, Feldman HI. Effect of anti-lymphocyte induction therapy on renal allograft survival: A meta analysis. *J Am Soc Nephrol*
5. Szczech LA, Berlin JA, Feldman HI. The effect of antilymphocyte induction therapy on renal allograft survival. A meta-analysis of individual patient-level data. Anti-Lymphocyte Antibody Induction Therapy Study Group. *AnnInternMed.* 1998;128(10):817?26.
6. Cai J, Terasaki PI. Induction immunosuppression improves long-term graft and patient outcome in organ transplantation: An analysis of United Network for Organ Sharing registry data. *Transplantation.* 2010;90(12):1511?5
7. Vincenti F, Kirkman R, Light S, Bumgardner G, Pescovitz M, Halloran P, et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study and survival after kidney transplantation: Systematic

8. Hooks MA. Tacrolimus, a new immunosuppressant--a review of the literature. *Ann Pharmacother*. 1994 Apr;28(4):501-11. doi: 10.1177/106002809402800414. PMID: 7518710.

Competing interests

The authors declare that they have no competing interests.

How to cite this article (Vancouver)

batra A. Kidney Transplant: Immunosuppressive Therapies and Complications. *CHEARS Chronical*. 2025;12(3):e159. Available from: <https://chears.in/journal/volume-12/issue-3/kidney-transplant-immunosuppressive-therapies-and-complications-159>

© 2025 The authors. Published by CHEARS in CHEARS Chronical.

<https://chears.in/journal/volume-12/issue-3/kidney-transplant-immunosuppressive-therapies-and-complications-159>